AstraZeneca plc (GB:AZN) has released an update.
AstraZeneca’s drug combo Truqap plus Faslodex has been recommended for EU approval for treating advanced ER-positive breast cancer, showing a 50% reduction in disease progression or death in a trial. This marks a significant advancement for patients with specific tumor biomarkers, providing a new treatment option for approximately half of the advanced HR-positive breast cancer population in Europe. The recommendation is based on the promising results of the CAPItello-291 Phase III trial, which could potentially change the practice for managing endocrine therapy resistance.
For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.
